THE BEST SIDE OF MOUNJARO

The demo realized both of those its Main endpoints, with semaglutide 2.4 mg demonstrating statistically major and outstanding advancements in liver fibrosis without worsening of steatohepatitis, in addition to resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH compared to placebo.1Assuming the above mentioned s